Acasti Pharma Inc
XTSX:ACST
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Acasti Pharma Inc
Free Cash Flow
Acasti Pharma Inc
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Acasti Pharma Inc
XTSX:ACST
|
Free Cash Flow
-$15.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Free Cash Flow
$993m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
4%
|
CAGR 10-Years
-7%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Free Cash Flow
-CA$86.7m
|
CAGR 3-Years
46%
|
CAGR 5-Years
36%
|
CAGR 10-Years
-11%
|
|
|
Cronos Group Inc
TSX:CRON
|
Free Cash Flow
-$190k
|
CAGR 3-Years
87%
|
CAGR 5-Years
75%
|
CAGR 10-Years
22%
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Free Cash Flow
-$113.9m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-42%
|
CAGR 10-Years
-117%
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Free Cash Flow
CA$35.3m
|
CAGR 3-Years
22%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
20%
|
|
Acasti Pharma Inc
Glance View
Acasti Pharma, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. The firm is targeting three underserved orphan diseases: Subarachnoid Hemorrhage (SAH), Ataxia Telangiectasia (A-T), and Postherpetic Neuralgia (PHN). The firm's lead product candidate includes GTX-104, which is a clinical-stage nanoparticle formulation of nimodipine being developed for IV infusion in SAH patients. The firm's other pipeline products include GTX-102, an oral mucosal spray formulation of betamethasone intended to develop neurological symptoms of A-T, including developing clinical assessments of posture and gait disturbance, and kinetic speech and oculomotor functions. GTX-101 is a topical bio-adhesive film-forming spray of bupivacaine for the treatment of PHN.
See Also
What is Acasti Pharma Inc's Free Cash Flow?
Free Cash Flow
-15.9m
USD
Based on the financial report for Mar 31, 2023, Acasti Pharma Inc's Free Cash Flow amounts to -15.9m USD.
What is Acasti Pharma Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 1Y
8%
Over the last year, the Free Cash Flow growth was 8%.
